You are here

Binosto (Alendronate Sodium) Available in U.S. for Treatment of Osteoporosis

Effervescent tablets dissolve in water to form buffered solution (Oct. 11)
Binosto delivers alendronate sodium in a once-weekly, buffered solution, which should benefit patients who prefer not to swallow tablets, suffer with dysphagia, or have other medical difficulties swallowing pills.

Although osteoporosis is often thought of as a disease that affects mostly women, the disorder also occurs in men. While women experience relatively rapid bone loss in the first few years after menopause, by about age 65, men and women lose bone mass at the same rate. Osteoporosis affects more than 200 million women and men worldwide and more than 10 million people in the U.S.

Binosto is a once-weekly, strawberry-flavored effervescent tablet containing alendronate sodium (70 mg) that rapidly dissolves in half a glass (4 oz) of room-temperature water to make a buffered solution. The product is available in packs of four.

For more information, visit the Mission Pharmacal Company Web site.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs